Eupraxia Pharmaceuticals (NASDAQ:EPRX) Trading Down 1.7% - What's Next?

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX - Get Free Report) shares dropped 1.7% during trading on Monday . The company traded as low as $4.18 and last traded at $4.08. Approximately 3,152 shares were traded during trading, a decline of 81% from the average daily volume of 16,604 shares. The stock had previously closed at $4.15.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on Eupraxia Pharmaceuticals in a report on Friday, February 21st. They set a "buy" rating and a $12.00 price objective for the company.

Eupraxia Pharmaceuticals Trading Down 0.5 %

The business has a fifty day simple moving average of $3.42 and a 200 day simple moving average of $3.07. The stock has a market capitalization of $148.25 million and a P/E ratio of -5.78.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Millennium Management LLC bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $31,000. Raymond James Financial Inc. bought a new position in shares of Eupraxia Pharmaceuticals in the fourth quarter valued at approximately $37,000. Finally, Bank of Montreal Can grew its holdings in shares of Eupraxia Pharmaceuticals by 15.2% in the fourth quarter. Bank of Montreal Can now owns 56,750 shares of the company's stock valued at $178,000 after acquiring an additional 7,500 shares in the last quarter.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.